Prime award
MATRISOME BIO, INC. · Department of Health and Human Services
NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC)
Current value$299K
Obligated to date$0
Months remaining0
Sign in to mark this as watching, pursuing, or passed — and to be told when its end date changes.
Recompete signal
This award ends in 0 months.
Award record
| Field | Value |
|---|---|
| Recipient | MATRISOME BIO, INC. |
| Awarding agency | Department of Health and Human Services |
| NAICS | 541715 |
| PSC | AN12 |
| Place of performance | MA |
| Period | → Sep 14, 2026 |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Competition | D |
| Offers received | 55 |
| Vehicle | Standalone |
Data & sources
Record as published by USAspending.gov, vintage FY2021–FY2025 full archives · USAspending.gov, retrieved Aug 6, 2026. Values change as modifications are reported; obligations may be negative when work is de-obligated.